93 related articles for article (PubMed ID: 16899786)
1. Imatinib and altered bone and mineral metabolism.
Owen S; Hatfield A; Letvak L
N Engl J Med; 2006 Aug; 355(6):627; author reply 628-9. PubMed ID: 16899786
[No Abstract] [Full Text] [Related]
2. Imatinib and altered bone and mineral metabolism.
Joensuu H; Reichardt P
N Engl J Med; 2006 Aug; 355(6):628; author reply 628-9. PubMed ID: 16903020
[No Abstract] [Full Text] [Related]
3. Imatinib and altered bone and mineral metabolism.
Tournis S; Lyritis GP
N Engl J Med; 2006 Aug; 355(6):627; author reply 628-9. PubMed ID: 16906646
[No Abstract] [Full Text] [Related]
4. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
5. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
Grey A; O'Sullivan S; Reid IR; Browett P
N Engl J Med; 2006 Dec; 355(23):2494-5. PubMed ID: 17151376
[No Abstract] [Full Text] [Related]
7. Imatinib as a possible cause of severe rhabdomyolysis.
Penel N; Blay JY; Adenis A
N Engl J Med; 2008 Jun; 358(25):2746-7. PubMed ID: 18565874
[No Abstract] [Full Text] [Related]
8. Another look at imatinib mesylate.
Schellings MW; Löwenberg B; Pinto YM
N Engl J Med; 2007 Mar; 356(11):1183; author reply 1183. PubMed ID: 17361003
[No Abstract] [Full Text] [Related]
9. Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?
Distler JH; Distler O
Ann Rheum Dis; 2007 Jun; 66(6):836. PubMed ID: 17513571
[No Abstract] [Full Text] [Related]
10. Dermatological toxicity of imatinib mesylate.
Prasad N; Deshmukh C; Biswas G; Bakshi A; Sastry PS; Parikh PM
J Assoc Physicians India; 2005 Apr; 53():298. PubMed ID: 15987015
[No Abstract] [Full Text] [Related]
11. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
Srinivas U; Pillai LS; Kumar R; Pati HP; Saxena R
Am J Hematol; 2007 Apr; 82(4):314-6. PubMed ID: 17013815
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of imatinib--dissecting heart from the rest.
Thachil J
Cancer; 2011 Jan; 117(1):228; author reply 228-9. PubMed ID: 20806351
[No Abstract] [Full Text] [Related]
13. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
14. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
15. Imatinib: cardiac risks?
Prescrire Int; 2007 Apr; 16(88):72. PubMed ID: 17465036
[No Abstract] [Full Text] [Related]
16. Loss of skin pigment caused by imatinib therapy.
McPartlin S; Leach M
Br J Haematol; 2005 May; 129(4):448. PubMed ID: 15877727
[No Abstract] [Full Text] [Related]
17. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
18. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.
Mahapatra M; Mishra P; Kumar R
Ann Hematol; 2007 Jul; 86(7):537-8. PubMed ID: 17287945
[No Abstract] [Full Text] [Related]
19. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
Osorio S; Noblejas AG; Durán A; Steegmann JL
Am J Hematol; 2007 May; 82(5):394-5. PubMed ID: 17117416
[TBL] [Abstract][Full Text] [Related]
20. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib.
Hamberg P; de Jong FA; Boonstra JG; van Doorn J; Verweij J; Sleijfer S
J Clin Oncol; 2006 Jun; 24(18):e30-1. PubMed ID: 16782905
[No Abstract] [Full Text] [Related]
[Next] [New Search]
